Senseonics, a company developing an implantable continuous glucose monitoring (CGM) system announced that Eversense users who use the new app can start dosing insulin based on readings from their system without first doing a fingerstick.
“We’re very pleased that today, the new Eversense app is available from the Apple App and Google Play stores, so now users in the United States can take full advantage of being able to make treatment decisions without the need to test their blood glucose levels,” said Dr. Tim Goodnow, president, and chief executive officer at Senseonics.
“It’s a testament to the proven and robust Eversense technology that only a year after entering the U.S. market, we can enhance the user experience by providing this updated indication,” he added.
Goodnow also stated that with Eversense designated as a therapeutic CGM, Medicare beneficiaries will soon be able to use Eversense CGM as part of their diabetes treatment plan in 2020.
How Does It Work?
The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends, and alerts.
In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor.
The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure. With the non-adjunctive claim, the Eversense CGM System will still require 2 calibrations a day.
Patients who are interested in getting started on Eversense, now with fewer fingersticks, can sign up at www.eversensediabetes.com/get-started-today.
Physicians, nurse practitioners or physician assistants interested in offering the Eversense CGM System for their patients can contact 844-SENSE4U (844-736-7348).
- Senseonics Holdings, Inc. (2019, Dec 9). Senseonics Launches Eversense CGM System with Non-Adjunctive Claim in the U.S. Business Wire. Retrieved Dec 9, 2019, from https://www.businesswire.com/news/home/20191202005864/en